301 related articles for article (PubMed ID: 25029255)
21. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion.
Qian T; Zhao M; Wan Y; Li M; Xu X
BMJ Open; 2018 Dec; 8(12):e022700. PubMed ID: 30593547
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of anti-VEGF agents for diabetic macular edema.
Ollendorf DA; Colby JA; Pearson SD
Int J Technol Assess Health Care; 2013 Oct; 29(4):392-401. PubMed ID: 24290332
[TBL] [Abstract][Full Text] [Related]
24. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.
Baker CW; Glassman AR; Beaulieu WT; Antoszyk AN; Browning DJ; Chalam KV; Grover S; Jampol LM; Jhaveri CD; Melia M; Stockdale CR; Martin DF; Sun JK;
JAMA; 2019 May; 321(19):1880-1894. PubMed ID: 31037289
[TBL] [Abstract][Full Text] [Related]
25. The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema.
Ishibashi T; Li X; Koh A; Lai TY; Lee FL; Lee WK; Ma Z; Ohji M; Tan N; Cha SB; Shamsazar J; Yau CL;
Ophthalmology; 2015 Jul; 122(7):1402-15. PubMed ID: 25983216
[TBL] [Abstract][Full Text] [Related]
26. Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
Maturi RK; Glassman AR; Josic K; Baker CW; Gerstenblith AT; Jampol LM; Meleth A; Martin DF; Melia M; Punjabi OS; Rofagha S; Salehi-Had H; Stockdale CR; Sun JK;
JAMA; 2023 Feb; 329(5):376-385. PubMed ID: 36749332
[TBL] [Abstract][Full Text] [Related]
27. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
Krick TW; Bressler NM
Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
[TBL] [Abstract][Full Text] [Related]
28. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
29. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
Wells JA; Glassman AR; Jampol LM; Aiello LP; Antoszyk AN; Baker CW; Bressler NM; Browning DJ; Connor CG; Elman MJ; Ferris FL; Friedman SM; Melia M; Pieramici DJ; Sun JK; Beck RW;
JAMA Ophthalmol; 2016 Feb; 134(2):127-34. PubMed ID: 26605836
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study.
Li X; Dai H; Li X; Han M; Li J; Suhner A; Lin R; Wolf S;
Graefes Arch Clin Exp Ophthalmol; 2019 Mar; 257(3):529-541. PubMed ID: 30645696
[TBL] [Abstract][Full Text] [Related]
31. The Efficacy and Safety of Current Treatments in Diabetic Macular Edema: A Systematic Review and Network Meta-Analysis.
Zhang L; Wang W; Gao Y; Lan J; Xie L
PLoS One; 2016; 11(7):e0159553. PubMed ID: 27434498
[TBL] [Abstract][Full Text] [Related]
32. Laser photocoagulation for proliferative diabetic retinopathy.
Evans JR; Michelessi M; Virgili G
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD011234. PubMed ID: 25420029
[TBL] [Abstract][Full Text] [Related]
33. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
Jampol LM; Glassman AR; Bressler NM; Wells JA; Ayala AR;
JAMA Ophthalmol; 2016 Dec; 134(12):. PubMed ID: 27711918
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective.
Adedokun L; Burke C
Adv Ther; 2016 Jan; 33(1):116-28. PubMed ID: 26747252
[TBL] [Abstract][Full Text] [Related]
35. Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry.
Bhandari S; Nguyen V; Fraser-Bell S; Mehta H; Viola F; Baudin F; Gabrielle PH; Creuzot-Garcher C; Gillies M; Barthelmes D
Ophthalmology; 2020 May; 127(5):608-615. PubMed ID: 31932092
[TBL] [Abstract][Full Text] [Related]
36. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
Wykoff CC; Brown DM; Maldonado ME; Croft DE
Br J Ophthalmol; 2014 Jul; 98(7):951-5. PubMed ID: 24518078
[TBL] [Abstract][Full Text] [Related]
37. Anti-VEGF for the management of diabetic macular edema.
Stefanini FR; Badaró E; Falabella P; Koss M; Farah ME; Maia M
J Immunol Res; 2014; 2014():632307. PubMed ID: 24741610
[TBL] [Abstract][Full Text] [Related]
38. Functional and structural efficacy of a novel combinational therapy of aflibercept and timely focal/grid photocoagulation in diabetic macular oedema: do clinical study results compare favourably with a standard-of-care treated real-world population?
Jørgensen MM; Vestergaard AH; Blindbaek SL; Peto T; Grauslund J
Acta Ophthalmol; 2022 Dec; 100(8):e1624-e1629. PubMed ID: 35673897
[TBL] [Abstract][Full Text] [Related]
39. Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors.
Chatzirallis A; Theodossiadis P; Droutsas K; Koutsandrea C; Ladas I; Moschos MM
Cutan Ocul Toxicol; 2020 Dec; 39(4):317-322. PubMed ID: 32722955
[TBL] [Abstract][Full Text] [Related]
40. Subthreshold Compared with Threshold Macular Photocoagulation for Diabetic Macular Edema: A Systematic Review and Meta-Analysis.
Tai F; Nanji K; Garg A; Zeraatkar D; Phillips M; Steel DH; Garg SJ; Kaiser PK; Guymer RH; Wykoff CC; Sivaprasad S; Chaudhary V
Ophthalmol Retina; 2024 Mar; 8(3):223-233. PubMed ID: 37805099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]